Wah... OKU_2020 a.k.a The Spammer Dog dengan multi ID sedang buat kacau.

Sudah disahkan OKU_2020 dan pemburuscammer dan 3 ID lainnya di dalam forum ini menggunakan IP address yang sama.

KEJAHATAN kamu sudah terdedah.... Siapa yang BERPELUH tentulah ORANG YANG SALAH..

KETIDAK SIUMAN sekaranglah padah...

PERCAYA DENGAN ORANG YANG BERMUKA EMPAT?? Kesian

whistlebower99 Another loss making penny stock waiting for share consolidation and rights issue to collect more money from shareholders like MZMZ511.
---------------------
Kita mungkin boleh perhatikan kebanyakan syarikat yang buat consolidation ialah apabila syarikat mengalami kerugian terkumpul yang banyak selain daripada NOSH yang besar. Banyak syarikat yang mempunyai masalah kerugian terkumpul yang besar akan buat capital reduction bersama-sama dengan proses consolidation.

Dan biasanya, syarikat yang mempunyai BOD yang hanya memiliki peratus saham yang sedikit biasanya suka buat consolidation. Ini kerana kesan negatif consolidation banyak ditanggung oleh pelabur runcit berbanding pemegang saham insider.

NOSH yang besar bukan jadi sebab mewajibkan sesebuah syarikat membuat consolidation. Kecualilah:

1. Keadaan kewangan syarikat amat memerlukan consolidation dibuat, contohnya dalam keadaan kerugian terkumpul yang banyak dalam kunci kira-kira.

2. Atau ada UDANG DISEBALIK BATU dalam kalangan pengurusan sesebuah syarikat tertentu.

JIKA NOSH besar, keadaan kewangan okay, harga saham pun OKAY, syarikat tersebut rasanya tak perlu buat consolidation. LIHAT SAJA CONTOH MY E.G. Bukannya nak buat consolidation tetapi menambahkan lagi jumlah NOSH syarikat sampai 8 bilion unit melalui Bonus Issue.

KAJIAN KES MELIBATKAN NEXGRAM:
1. Nexgram telah melaksanakan capital reduction dan ianya akan secara rasmi diambil kira ke dalam akaun bagi 4QR 2021. Semua kerugian terkumpul akan di offsett dengan perolehan capital reduction dan kunci kira-kira akan mula menunjukkan baki retained earning bermula dalam akaun 4QR 2021.
2. Berlaku perubahan struktur pemegangan saham dalam Nexgram. Pemegang saham dari kalangan BOD telah bertambah, contohnya Hj Mazru telah pegang kepentingan 7% dan ianya mungkin akan ditingkatkan sehingga 25% kepentingan saham.

Kesimpulan: Atas dasar tiada lagi masalah kerugian terkumpul yang besar dalam syarikat dan kepentingan saham yang dipegang dari kalangan insider syarikat adalah besar, maka saya rasa kemungkinan syarikat untuk membuat consolidation adalah lebih rendah.

Nota sebagai rujukan.

Capital reduction = Kurangkan modal saham, kesannya mungkin mempengaruhi par value saham. Boleh dilaksanakan untuk syarikat yang mempunyai keuntungan terkumpul atau pun kerugian terkumpul.

Consolidation = Kumpulkan beberapa unit saham sedia ada menjadi satu unit saham. Contoh 10 saham dikumpulkan menjadi satu saham. Boleh juga dibuat untuk syarikat yang mengalami keuntungan dan syarikat yang mengalami kerugian terkumpul yang banyak. tetapi consolidation lebih biasa dibuat untuk syarikat yang mengalami kerugian.

@wistlebower99. I invested in this company started from few years ago. I agree with you about the past records of the company which always in red started from FY 2016 up to FY 2020. Before that the company's FY was profitable.

We simply can refer here to confirm it:
https://klse.i3investor.com/servlets/stk/fin/0096.jsp

But started from 2QR 2021 of FY 2021, there are some improvement has been reported in term of revenue and profitability of the company. Also it shareholder equity on consolidated basis of its shares excluding treasury shares has been improved @ above 50%. A great achievement for the company in turning around its FA conditions. All these improvement almost because of its new busineses related to healthcare / medical.

Please refer to my articles:

1. https://klse.i3investor.com/blogs/mzm511/2021-07-01-story-h1567122502-SOME_ANALYSIS_FROM_THE_3QR_2021_OF_NEXGRAM_0096.jsp

2. https://klse.i3investor.com/blogs/MZM2511/2021-05-11-story-h1565005629-The_Competitive_Edge_of_NEXGRAM_0096_in_Vaccine_Passports_and_Digital_F.jsp

3. https://klse.i3investor.com/blogs/mzm511/2021-06-14-story-h1566192317-The_Current_Status_of_MOU_and_Agreements_Relating_To_NEXGRAM_0096.jsp

@whistlebower99. Good to hear that you're starting to alert on accounting parts of this company.

@justin1njp. Indeed. It's true.

@wistlebower99. To analyse on the financial conditions about certain company, you have to know basic thing about accounting or finance theories.

Please don't give any conclusion about a company without knowing any basic knowledge of accounting or finance. You will be A BLIND PARROT. Sorry.

@wistlebower99. How about the retained earning????
Its shows that Bornoil overally a profitable company.

Friends.

1. You better find more information about this issue. Better get true information based on what happened recently to the company after the company triggered with MUGC (GN3/PN17 listed issuer) but has been given relief.

Officially, currently Nexgram is not in the list of GN3 listed issuer company because it has given the relief by BURSA. The issues related to the MUGC which was triggered on Nexgram can be
read at: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3099172


2. Based on the 3Q 2021 report, Nexgram's shareholder equity on consolidated basis of its shares excluding treasury shares

= (RM121,482,625 ÷ 215,119,923) x 100%

= 56.47 %

Conclusion:

3QR on 2QR, shareholder's equity of its shares increased from 51.23% in the last 2QR 2021 report to 56.47%.
@@Remarks: GN3 risk ?? Lowered

Source: https://klse.i3investor.com/blogs/mzm511/2021-07-01-story-h1567122502-SOME_ANALYSIS_FROM_THE_3QR_2021_OF_NEXGRAM_0096.jsp


3. Nexgram won’t be listed as GN3 issuers because:

a. The capital reduction has been approved and be executed. Its can helps to clear off the accumulated losses in the companys account, and the company will record the small accumulated profit in the company’s account.

b. Nexgram's shareholders equity on consolidated basis of its shares (excluding treasury shares)
in 3QR 2021 was getting better, already at 56.27%.

c. There is no more new MUGC triggered in FY 2020 up to today because its shareholders equity on consolidated basis of its shares (excluding treasury shares) has surpassed the 50% figure.

stockraider Avoid lah!

konman counter mah!
------------

Even DPharma also can be classified as a con counter.
Especially if you were trapped at the higher price, and now the price of the counter is in downtrend.

He He

stockraider Avoid lah!

konman counter mah!
------------

Even DPharma also can be classified as a con counter.
Especially if you were trapped at the higher price, and now the price of the counter is in downtrend.

He He

@whistlebower99.

I WANT TO SHARE WITH YOU MY SIMPLE THEORY:

But as I looked at certain companies before, after the company approved the RI and setup the issue price for RI, the share price firstly will drop.

But near the date of the RI to be executed, the price will be markup higher than the issue price of the RI.

These scenario surely not be absolutely will happen to Kanger, but it has high chance or probability to follow suit.

AFTER ALL. TAYOR.

@whistlebower99.

Kanger is still in progressing state in its current businesses, which are a bamboo flooring and related products, and Kanger also in its plan to venture in other business activities.

1. The company already involved in the construction services.
2. In a process to acquire property for investment.
3. In a final process to acquire a company which involved in a construction material trading.
4. And of course a BONUS plan by the company to be involved in the Covid-19 vaccine business. Kanger is on the last step to procure 5 – 10 million doses of the Sinopharm vaccine for the sale in Malaysia. Hope to see the results in August 2021.

@whistlebower99.

Kanger's NOSH been uplifted in line for acquiring new projects or diversification. It was done for the development of the company businesses. The company is in their path to be more diversified and profitable.

----------------------------
On behalf of the Board, UOB Kay Hian wishes to announce that Bursa Securities had, vide its letter dated 30 June 2021, resolved to approve the listing and quotation of the following:-

i 713,157,273 new Kanger Shares to be issued pursuant to the Proposed Acquisition; and

ii. 769,513,179 new Kanger Shares to be issued pursuant to the Proposed Subscription

----------------------
and: Look at the good prospects from the proposed acquisition, for example:

https://www.theedgemarkets.com/article/kanger-confident-returning-black-fy22-driven-construction-business

@detouch. I am not in group. Only a very small trader cum investor. He He.
By the way, I have to protect my money invested in this counter.

Wah... OKU_2020 a.k.a The Spammer Dog dengan multi ID sedang buat kacau.

Sudah disahkan OKU_2020 and pemburuscammer and 3 ID lainnya di dalam forum ini menggunakan IP address yang sama.

KEJAHATAN kamu sudah terdedah....

KETIDAK SIUMAN sekaranglah padah.....

@hlh1962. From an announcement of the HOA to BURSA:

4.7 Conditions Precedent
The offer for this purchase shall be conditional upon the completion and/or satisfaction of the following conditions precedent within three (3) months from the date of the HOA.
a. The EUA is granted to the Products by the health authorities in Malaysia;
b. All required governmental and/or regulatory approvals have been obtained by the Supplier for the export of Products to the Territory whilst all required governmental and/or regulatory approvals have been obtained by the Buyer for the import and
c. Use of Products in the Territory on an emergency use basis, both in accordance with their respective local applicable laws;
d. The Supplier has successfully secured and entered into a purchase contract with the Manufacturer of the Products, for the purchase of the Products by the Supplier to be sold to the Buyer.

7. EFFECTIVE PERIOD
The Parties agreed that the HOA shall take effect as from the Effective Date. For the purpose of the HOA, Effective Date means the date on which the Emergency Use Authorization (“EUA”) is granted to the Product by the health authorities in Malaysia, provided that the EUA is granted within three (3) months as of the signature date of the HOA. Absent issuance of such EUA within such timeline, the Parties agreed that the HOA shall not enter into effect and shall be null and void.
EUA means an application for marketing authorisation to be granted on an “emergency use” or other provisional basis by the competent authority in the Territory. The Supplier acknowledges that, as of the date of the HOA, no EUA has been granted for the Product in the Territory.

Source: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3176295

My comment:
Yes. Based on the announcement, the company did not mentioned any news that the company has applied for the NPRA's approval, and its stated that at the date of HOA, no EUA has been granted for the Product in Malaysia.
-------------

But: Based on the report by Steven Kuah (BOD of kanger) which was quoted by The Edge, Kanger has submitted the application to obtain the approval of the Hayat-vax vaccine from the NPRA.

..............Furthermore, Kanger has also been authorised by G42 Medications to be the product registration holder and distributor of the Hayat-Vax vaccine in Malaysia.

On behalf of G42 Medications, Kanger has submitted the necessary applications to obtain the required approvals from the National Pharmaceutical Regulatory Agency (NPRA) for the Hayat-Vax vaccine to be used in the country.

Source: https://www.theedgemarkets.com/article/kanger-enters-deal-buy-five-million-doses-sinopharm-covid19-vaccines

https://klse.i3investor.com/blogs/mzm511/2021-07-01-story-h1567122502-SOME_ANALYSIS_FROM_THE_3QR_2021_OF_NEXGRAM_0096.jsp

Wah... OKU_2020 a.k.a The Spammer Dog dengan multi ID sedang buat kacau.

Sudah disahkan OKU_2020 and pemburuscammer and 3 ID lainnya di dalam forum ini menggunakan IP address yang sama.

KEJAHATAN kamu sudah terdedah....

KETIDAK SIUMAN sekaranglah padah.....

https://klse.i3investor.com/m/blog/mzm511/2021-07-01-story-h1567122502-SOME_ANALYSIS_FROM_THE_3QR_2021_OF_NEXGRAM_0096.jsp

Wah... OKU_2020 a.k.a The Spammer Dog dengan multi ID sedang buat kacau.

Sudah disahkan OKU_2020 and pemburuscammer and 3 ID lainnya di dalam forum ini menggunakan IP address yang sama.

KEJAHATAN kamu sudah terdedah....

KETIDAK SIUMAN sekaranglah padah.....

https://klse.i3investor.com/servlets/cube/oku_2020.jsp

https://klse.i3investor.com/servlets/cube/post/jualbeli69.jsp

https://klse.i3investor.com/servlets/cube/post/pemburuscammer.jsp

Boleh check. Ini mungkin ID klon OKU_2020 a.k.a The Spammer Dog yang cari makan dengan spam di kaunter ini.
Pakar dalam IT boleh sahkan.

Kalau nak menipu semua orang pun, biarlah berpada pada.

@OKU_2020 a.k.a MDP. Kalau macam tu, bukak lah lagi ID baru atas nama SiKentutPreq.

Mesti trending sebagai the spammer dog... HE HE

Net Profits and Net Assets of Techfast based on its latest audited consolidated
accounts

Year: 2007 2008 2009
Revenue 26,784,00 30,421,000 29,529,000
Profit before interest and tax 5,116,000 5,625,000 5,029,000
Profit Before Taxation 5,079,000 5,593,000 5,006,000
Profit After Taxation 3,671,000 3,980,000 3,505,000
Net Profit Margin 14% 13% 12%
Total Assets 29,454,000 30,982,000 32,472,000
Cash and Cash Equivalents 8,924,000 10,162,000 8,729,000

Prospects of Techfast

Techfast is principally involved in three main areas, (i) manufacturing and distribution
of high precision fasteners, (ii) mould cleaning and conditioning compound and (iii)
customised epoxy and colour dye formulation for the encapsulation of photonic devices.

Techfast had also recently undertaken a diversification and acquisition exercise.
Techfast intends to expand its business through exciting sector in the semi-conductor
sector. It has a healthy balance sheet, proven competitive and is a niche market.

THERE ARE SOME PLANS BY KANGER TO UPLIFT THE COMPANY BUSINESSES:

Kanger is still in progressing state in its current business, which are a bamboo flooring and related products, and Kanger also in its plan to venture in other business activities.

1. The company already involved in the construction services.
2. In a process to acquire property for investment.
3. In a final process to acquire a company which involved in a construction material trading.
4. And of course a BONUS plan by the company to be involved in the Covid-19 vaccine business. Kanger is on the last step to procure 5 – 10 million doses of the Sinopharm vaccine for the sale in Malaysia. Hope to see the results in August 2021.

@Hungrybird. But if you do not believe my analysis, you can do your own research from the company's 3QR 2021 report.

@Hungrybird.

Nexgram's shareholder equity on consolidated basis of its shares excluding treasury shares

= (RM121,482,625 ÷ 215,119,923) x 100%

= 56.47 %


Conclusion:

3QR on 2QR, shareholder's equity of its shares increased from 51.23% in the last 2QR 2021 report to 56.47%

@@Remarks: GN3 risk ?? Lowered
---------------
Please refer to:

https://klse.i3investor.com/blogs/mzm511/2021-07-01-story-h1567122502-SOME_ANALYSIS_FROM_THE_3QR_2021_OF_NEXGRAM_0096.jsp

OKU_2020 a.k.a MDP. You cakap sorang-sorang ke. Berapa banyak ID mau bukak.. He He

@Jointpains. Take your time to read some information on the article.

Do you think Nexgram have a high risk to be delisted?

https://klse.i3investor.com/blogs/mzm511/2021-07-01-story-h1567122502-SOME_ANALYSIS_FROM_THE_3QR_2021_OF_NEXGRAM_0096.jsp

For the newbie. Its okay. You have to consider also for those who kept the hare long time ago.
Please give more true stories about the company.
I want you to give better explanation on the risks of Nexgram to be delisted.

Do not just be a cheap plug key warrior here. Give full analysis that can be discussed here.

@Jointspains. Apasal. Bagus betul kasi bom sini.
Ada minat nak beli saham Nexgram yang nak bangkrap ke???
Atau ada orang gila yang baru terlepas tanjung rambutan???

@Jointspains. Wau dari mana datang ni...
Masuk-masuk dengan ID baharu terus merapu.
ID kembar siapa lah ni....He He

gohkimhock only pharmaceutical companies are allowed to be registered holder of vaccines.
---------------

A possibility.

The product registration holder will be given to Zuellig Pharma Sdn Bhd as there was an MOU for Kanger to collaborate with ZP to facilitate the import, warehousing, and distribution of Covid-19 vaccines in Malaysia.

Sinopharm will export/ship the Covid-19 vaccines to Malaysia. Services required from ZP are
importation upon arrival, warehousing, inventory management, pick, pack, delivery to
customers, collection & credit risk assumption.

and the MOU is still kicking as per latest announcement on 4 August 2021...

.....Reference is made to the announcements dated 26 October 2020, 9 March 2021 and 3 May 2021 pertaining to the MOU made between the Kanger and ZP for the purpose of collaboration on the distribution of Covid-19 vaccines in Malaysia.

The Board of Directors of Kanger wishes to announce that there is still waiting for delivery schedule from supplier and no further update in relation to the MOU.

This announcement is dated 4 August 2021.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3180964

----------------

And another possibility is:

"The Hayat-Vax vaccine is essentially the same Sinopharm Covid-19 vaccine, manufactured in the UAE. Hence, we are confident that it will be well-received and accepted by the Malaysian people as an effective vaccine towards the global fight against the Covid-19 pandemic," said Kuah.

Kanger has also been authorised by G42 to be the product registration holder and distributor of the Hayat-Vax vaccine in Malaysia.

On behalf of G42 Medications, Kanger said it had submitted applications to obtain the required approvals from the National Pharmaceutical Regulatory Agency for the Hayat-Vax vaccine to be used in Malaysia.

@olangbolo Dpharma bawa Sinopharm from China yg dah OFFicial Announce pun Xnaik,
Kanger yg xdapat lg NPRA, xtau lagi how genuine dgn UAE ko rasa boleh naik...
-------------
Moderna vaksin buatan Amerika Syarikat. Macam mana pula Moderna vaksin yang dikeluarkan oleh pengeluar di Sepanyol boleh diluluskan untuk kegunaan di Malaysia oleh NPRA?
SILA JAWAB YANG ARIF LAGI BIJAKSANA olangbolo..
..........................

The product registration holder is Zuellig Pharma Sdn Bhd and its manufacturer is Rovi Pharma Industrial Services from Spain.

So far, vaccines that have gained approval for Malaysia’s National Covid-19 Immunisation Programme are those from Pfizer-BioNTech, AstraZeneca, Sinovac, Sinopharm, Johnson & Johnson and CanSino

https://www.thestar.com.my/news/nation/2021/08/05/health-dg-conditional-approval-granted-for-moderna-covid-19-vaccine

@olangbolo...... Dpharma is bet on Sputnik, n otak tu jgn Tolol sgt.....
---------------
Mungkin ini salah satu sebab Dpharma tak naik kot.

Sputnik V: From vaccine hope to frustration for Latin America

.......Yet to receive UN approval, the vaccine has since been taken up by about a dozen countries in the region -- but, eight months in, a critical shortage of the second dose is weighing heavily on governments with limited alternatives.

Source: https://malaysia.news.yahoo.com/sputnik-v-vaccine-hope-frustration-015005120.html


Note: 1. Sputnik V belum lagi dapat NPRA aproval dan
2. BEKALAN VAKSIN YANG DIKELUARKAN PUN TAK CUKUP... He He

Based on 3QR 2021:

The status of the utilisation of the Proposed Subscription of up
to 1,205,827,550 new ordinary shares proceeds as at the date of this
announcement is as follows:

2 Gold exploration works at Hutan Simpan Bukit Ibam, Mukim Keratong, Pahang ("Plant")
Proposed utilisation RM1 0,000.000 Actual utilisation RM2 ,722 Within 36 months from the receipt of placement funds

@olangbolo.
Senang saja. DPharma joint terus perolehan vaksin Sinopharm dengan Beijing Institute of Biological Products Co. Ltd., SINOPHARM CNBG.

Bagi meneruskan perjanjian lantikan untuk edaran vaksin Sinopharm yang ditandatangani oleh anak syarikat Sinopharm dengan Kanger, maka saluran vaksin Sinopharm jenama Hayat-Vax keluaran kerjasama antara Sinopharm dengan pengeluar di UAE ditawarkan kepada Kanger.

Logik dari saya saja.

@olangbolo.
..... but I think the newly acquired businesses can give more security for the profitability of the company in medium and long term.

https://www.theedgemarkets.com/article/kanger-confident-returning-black-fy22-driven-construction-business

The cerdikman olangbolo, bolehkah beri analysis sendiri tentang kemungkinan keberuntungan syarikat Kanger. Sila beri.... Kami pun nak tengok.

@whistlebower99. I absolutely agree with your idea about the difference between the given two companies regarding to risks and FA conditions.

From my simple analysis regarding Kanger's current FA, the risks for Kanger is still low in terms of going concern factor, solvency and liquidity. The current problem is about profitability, but I think the newly acquired businesses can give more security for the profitability of the company in medium and long term.

Yes. Nanti kita cadang kat Kanger olangbolo jadi pengurus projek. Nanti semua projek boleh jalan.
Lain hasilnya jika orang cerdik olangbolo yang uruskan. He He

@whistlebower99.

Kanger's NOSH been uplifted in line for acquiring new projects or diversification. It was done for the development of the company businesses. The company is in their path to be more diversified and profitable.

----------------------------
On behalf of the Board, UOB Kay Hian wishes to announce that Bursa Securities had, vide its letter dated 30 June 2021, resolved to approve the listing and quotation of the following:-

i 713,157,273 new Kanger Shares to be issued pursuant to the Proposed Acquisition; and

ii. 769,513,179 new Kanger Shares to be issued pursuant to the Proposed Subscription

----------------------

and: Look at the good prospects from the proposed acquisition, for example:

https://www.theedgemarkets.com/article/kanger-confident-returning-black-fy22-driven-construction-business

@whistlebower99.

Fast Energy NOSH been uplifted in line for acquiring new projects or diversification. It was done for the development of the company businesses. The company is in their path to be more diversified and profitable.

@whistlebower99.

1. SAPNRG ( 5218 ) NOSH: 15.979 billion Current Price: RM0.12.

2. MY E.G ( 0138 ) NOSH: 3.772 billion (going to be more than 8 billion after the incoming Bonus Issue) Current price RM1.62

Do you think these two companies will propose consolidation exercises?

@witslebower99.

1. SAPNRG ( 5218 ) NOSH: 15.979 billion Current Price: RM0.12.

2. MY E.G ( 0138 ) NOSH: 3.772 billion (going to be more than 8 billion after the incoming Bonus Issue) Current price RM1.62


Do you think these two companies will propose consolidation exercises?

Should these company's share price be downgraded to RM0.005 ?

OKU_2020 a.k.a MDP. Spotted. He He

Awwww. OKU_2020 a.k.a MDP.

Its good the price keeps supported @6 sen. Its not 0.005 actually. He He

@BetterTommorrow. Be more specific please!!!

Some of the MOU/Agreements have been completed or in the process of completion.

Please refer this:

https://klse.i3investor.com/blogs/mzm511/2021-06-07-story-h1566103030-The_Currents_Status_of_MOUs_and_Agreements_Relating_To_KANGER_0170.jsp

As a conclusion, the 'VACCINE GAME' for Kanger is still ON..

Reference is made to the announcements dated 26 October 2020, 9 March 2021 and 3 May 2021 pertaining to the MOU made between the Kanger and ZP for the purpose of collaboration on the distribution of Covid-19 vaccines in Malaysia.

The Board of Directors of Kanger wishes to announce that there is still waiting for delivery schedule from supplier and no further update in relation to the MOU.

This announcement is dated 4 August 2021.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3180964

Reference is made to the announcements dated 26 October 2020, 9 March 2021 and 3 May 2021 pertaining to the MOU made between Kanger and K-Star for the purpose of appointing K-Star (or its subsidiary) as the sale agent of Covid-19 vaccines for the private clinics in Malaysia.

The Board of Directors of Kanger wishes to announce that there is still waiting for delivery schedule from supplier and no further update in relation to the MOU.

This announcement is dated 4 August 2021.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3180966

@Beautyseeker. Kanger is beautiful enough for you to choose as one of your counter for investment. He He. TAYOR